In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to recognize safe dosing program. Additional individuals are going to be enrolled on the determined monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be presented as "insert-on" therapy. https://abbv-744-clinical-trial-p13578.dgbloggers.com/32359755/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options